Endostatin: A promising drug for antiangiogenic therapy

International Journal of Biological Markers

Volumn 14, Issue 4, 1999, Pages 263-267

  Cirri, L ^c   Donnini, S ^c   Morbidelli, L ^c   Chiarugi, P ^a   Ziche, M ^a,b   Ledda, F ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Università di Firenze ^*

Author keywords

Angiogenesis inhibitor; Antioangiogenic therapy; Endostatin

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEIN; THROMBOCYTE FACTOR 4; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

ANIMALIA; PROKARYOTA;

EID: 0033394092     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400412     Document Type: Conference Paper

References (33)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Hanahan D, Folkman J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
4. Risau W. Mechanism of angiogenesis. Nature 1997; 386: 671-4.
5. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
6. Ferrara N, Davis Smith T. The biology of vascular endothelial growth factor. Endocrine Rev 1997; 18: 4-25.
7. Bickfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2 (FGF-2). Endocrine Rev 1997; 18: 26-45.
8. O'Really MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
9. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor angiostatin. Cancer Res 1996; 56: 4887-90.
10. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblast by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
11. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1991; 247: 77-9.
12. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182 (1): 155-62.
13. O'Really MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
14. Standker L, Schrader M, Kause S, et al. Isolation and characterization of the circulating human endostastin. FEBS Lett 1997; 420: 129-33.
15. Homandberg GA, Williams JE, Grant DBS, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Path 1985; 120: 327-32.
16. Ferrara N, Clapp C, Weiner RI. The 16 kDa fragment of prolactin specifically inhibits basal or fibroblast growth factor-stimulated growth of capillary endothelial cells. Endocrinology 1991; 129: 896-900.
17. Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Comm 1999; 255: 735-9.
18. Muragaki Y, Timmons S, Griffith CM, et al. Mouse Coll 18 a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA 1995; 92: 8763-7.
19. Rehn M, Pihlajaniemi T. Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. J Biol Chem 1995; 270: 4705-11.
20. Schuppan D, Cramer T, Bauer M, et al. Hepatocytes as a source of collagen type XVIII endostatin. Lancet 1998; 352: 879-80.
21. Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998; 17:1656-64.
22. Boehm T, Pirie-Shepherd S, Trinh LB, et al. Destruction of the KEX-1 gene in Pichia pastoris allows expression of full-length murine and human endostatin. Yeast 1999; 15: 563-72.
23. Ding YH, Javaherian K, Lo KM, et al. Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci USA 1998; 95: 10443-8.
24. Boehm T, O' Really MS, Keough K, et al. Zinc-binding of endostatin is essential for its anti angiogenic activity. Biochem Biophys Res Comm 1998; 252: 190-4.
25. Boehm T, Folkman J, Browder T, O'Really MS. Anti angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
26. Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression and in vitro activity of human endostatin. Biochem Biophys Res Comm 1999; 258: 345-52.
27. Chang Z, Choon A, Friedl A, et al. Endostatin binds two blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 1999; 155: 71-6.
28. Dhanabal M, Ramchandran R, Waterman M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-6.
29. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335-6.
30. Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189-97.
31. Romanos MA, Scorer CA, Clare JJ. Foreign gene expression in yeast: a review. Yeast 1992; 8: 423-8.
32. Nguyeu JT, Wu P, Clouse ME, et al. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 1998; 58: 5673-7.
33. Taddei L, Chiarugi P, Brogelli L, et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Comm 1999; 263: 340-5.